drugset / Trial / NCT04659785
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
NaSingle-groupOpen-labelTreatment
Summary
This open-label, dose finding phase Ib trial studies the tolerability and the best dose of fluzoparib in combination with apatinib and to see how well these two drugs work together as second-line treatment of patients with extensive stage small cell lung cancer. The safety and efficacy of fluzoparib in combination with apatinib will be explored. Both dose escalation and dose expansion parts are included in this study.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2021-07-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | 50 mg | Oral |
| Subject | Fluzoparib | Small molecule | 100 mg | Oral |
| Subject | Rivoceranib | Small molecule | 375 mg | Oral |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Subject | Rivoceranib | Small molecule | 750 mg | Oral |